Taysha Gene Therapies to Release First Quarter 2022 Financial Results and Host Conference Call and Webcast on May 16

Rhea-AI Summary

Taysha Gene Therapies, Inc. (Nasdaq: TSHA) will release its financial results for Q1 2022 on May 16, 2022, at 8 AM Eastern Time. The pivotal-stage gene therapy company focuses on AAV-based treatments for monogenic CNS diseases. Following the earnings call, investors will receive updates on the company's progress and pipeline. Interested participants can join the call by dialing 877-407-0792 (toll-free) or 201-689-8263 (international), with the conference ID 13729044. Further information is accessible through their webcast.

DALLAS, May 11, 2022 (GLOBE NEWSWIRE) -- Taysha Gene Therapies, Inc. (Nasdaq: TSHA), a patient-centric, pivotal-stage gene therapy company focused on developing and commercializing AAV-based gene therapies for the treatment of monogenic diseases of the central nervous system (CNS) in both rare and large patient populations, today announced that it will report its financial results for the first quarter ended March 31, 2022, and host a corporate update conference call and webcast on Monday, May 16, 2022, at 8:00 AM Eastern Time.

Conference Call Details
Monday, May 16, at 8:00 AM Eastern Time / 7:00 AM Central Time
Toll Free:		877-407-0792
International:		201-689-8263
Conference ID:		13729044
Webcast:		https://ir.tayshagtx.com/news-events/events-presentations

About Taysha Gene Therapies        

Taysha Gene Therapies (Nasdaq: TSHA) is on a mission to eradicate monogenic CNS disease. With a singular focus on developing curative medicines, we aim to rapidly translate our treatments from bench to bedside. We have combined our team’s proven experience in gene therapy drug development and commercialization with the world-class UT Southwestern Gene Therapy Program to build an extensive, AAV gene therapy pipeline focused on both rare and large-market indications. Together, we leverage our fully integrated platform—an engine for potential new cures—with a goal of dramatically improving patients’ lives. More information is available at www.tayshagtx.com.

Company Contact:
Kimberly Lee, D.O.
Chief Corporate Affairs Officer
Taysha Gene Therapies
klee@tayshagtx.com

Media Contact:
Carolyn Hawley
Canale Communications
carolyn.hawley@canalecomm.com

FAQ

When will Taysha Gene Therapies report its Q1 2022 financial results?

Taysha Gene Therapies will report its Q1 2022 financial results on May 16, 2022, at 8 AM Eastern Time.

What is the conference call number for Taysha Gene Therapies' Q1 earnings report?

The toll-free conference call number is 877-407-0792, and the international number is 201-689-8263.

What is the purpose of Taysha Gene Therapies' upcoming conference call?

The conference call will provide financial results for Q1 2022 and a corporate update on the company's progress.

What is Taysha Gene Therapies' focus in its gene therapy research?

Taysha Gene Therapies focuses on developing AAV-based gene therapies for treating monogenic diseases of the central nervous system.

How can I access the webcast for Taysha Gene Therapies' corporate update?

You can access the webcast for the corporate update at this link.